Targeted treatment for advanced cancers using antibody-based therapies
Official title: Spatially precise radio-chemo-immunotherapy using antibody conjugates
Funded at University of California, San Diego · NIH-11001443 · Data updated 2026-11-12
This study is testing a new way to treat locally advanced cancers by using special drugs that target cancer cells directly, combined with traditional chemotherapy and radiation, to help improve treatment results and reduce side effects for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | December 1, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $533,079 |
| NIH project number | 5R01CA268513-03 |
| Project ID | NIH-11001443 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with locally advanced cancers who have not responded adequately to standard treatments.
✕Less likely to help
Patients with early-stage cancers or those whose tumors do not express the targeted receptors may not benefit from this research.
What this research studies
This research focuses on improving treatment for locally advanced cancers by combining targeted therapies with traditional chemotherapy and radiotherapy. It utilizes antibody-drug conjugates (ADCs) that specifically target tumor cells, allowing for the delivery of potent drugs directly to the cancer while minimizing damage to healthy tissues. The approach aims to enhance the immune response against tumors and improve overall treatment outcomes. By using advanced drug delivery systems, the research seeks to optimize the effectiveness of existing cancer treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less harmful treatments for patients with advanced cancers.
How similar studies have gone: Previous research has shown promise in using targeted therapies and antibody-drug conjugates for cancer treatment, indicating a potential for success with this approach.
Where this research is happening
-
University of California, San Diego
La Jolla, United States Active
Researchers
- Principal investigator: Advani, Sunil J — University of California, San Diego
- Study coordinator: Advani, Sunil J
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.